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In this issue of Cell Host & Microbe, Chang and Ganem (2013) report that Kaposi’s sarcoma-associated
herpesvirus infection of lymphatic endothelial cells (LECs), but not blood endothelial cells (BECs), activates
mTORC1 signaling and sensitizes LECs to rapamycin-induced killing. The differential rapamycin sensitivity is
explained by a unique LEC-specific virus latency program.Kaposi’s sarcoma-associated herpes-
virus (KSHV) is the causative agent of
Kaposi’s sarcoma (KS) and certain
lymphoproliferations, including primary
effusion lymphoma (PEL) and a subset of
multicentric Castleman’s disease (Mesri
et al., 2010). KS is the most common
neoplasm in untreated HIV-1-infected in-
dividuals. KS also occurs in elderly men
of East European or Mediterranean
descent (so-called ‘‘classic KS’’) and is
more widespread and aggressive in other
acquired immune deficiency states,
including after an organ transplant. The
optimal approach to managing posttrans-
plant KS is to reduce or discontinue
immunosuppressive therapy, but this
strategy carries the risk of acute graft
rejection. More recently, the use of an
mTOR inhibitor like rapamycin (sirolimus)
has added new opportunities to treat or
even prevent posttransplant KS (Stallone
et al., 2005). Whether rapamycin is effec-
tive in posttransplant KS due to its modu-
lation of immunosuppression or whether it
has direct anti-KSHV (Nichols et al., 2011)
or anti-KS tumor cell (Roy et al., 2013)
activity remains unclear.
To further elucidate the mechanism of
action of rapamycin in KS, Chang and
Ganem (2013) employed a dual reporter
recombinant virus, rKSHV.219, and in-
fected primary dermal microvascular
lymphatic endothelial cells (LECs) and
blood vessel endothelial cells (BECs) to
generate two polyclonal stably infected
lines, LEC.219 and BEC.219. Examining
the response of these two infected cell
lines to rapamycin, Chang and Ganem
reveal an unexpected addiction of
KSHV-infected LECs, but not BECs, to
mTOR signaling.
KSHV infection of endothelial cells
usually transforms them from cobble-stone to spindle shape, reminiscent of
the KSHV-infected tumor cells (i.e., spin-
dle cells) in KS lesions. The spindling
observed by Chang and Ganem in
LEC.219 but not BEC.219 was one of
the first clues that there may be a
difference in virus gene expression
between these two cell lines. Spin-
dling is mainly due to NF-kB activation,
which can be mediated by several viral
proteins, including vFLIP and vGPCR.
Gene expression was analyzed in
LEC.219 and BEC.219 by a custom
genomic KSHV tiling microarray and
with antibodies against specific viral
proteins (Chang and Ganem, 2013).
They show that, although both lines
are persistently infected, the expression
profile of these lines is diverse; infected
BECs follow the canonical latent pro-
gram, whereas in addition to the classic
latent cycle transcripts, LECs also ex-
press numerous genes characteristic of
lytic infection, including RTA, K-bZIP,
and ORF45.
KSHV, like other herpesviruses, is
thought to have two phases of gene
expression, latent and lytic replication;
during latency only a handful of viral
transcripts are expressed. In contrast,
the lytic phase involves the tempo-
rally regulated expression of the entire
viral genome, viral DNA replication,
and production of infectious progeny.
Chang and Ganem challenge this
dogma, suggesting that during latency
KSHV induces different gene expres-
sion profiles in different endothelial
lineages. Furthermore, they pin down
the selective mTOR signaling in LECs to
the expression of a specific viral gene,
ORF45.
KSHV can activate the PI3K/AKT/
mTOR pathway using several mecha-Cell Host & Microbenisms, including virus binding to host
cells. Viral proteins including K1, vGPCR,
and vIL6 have been implicated in PI3K/
AKT activation (Bhatt and Damania,
2012). Chang and Ganem suggest that
mTORC1 is activated in infected LECs
by dampening the activity of the negative
regulator, tuberous sclerosis complex
(TSC), specifically TSC2. Their data sug-
gest that TSC2 is phosphorylated and
suppressed by ERK2-mediated activation
of RSK1 and not by the classic PI3K/AKT
signaling pathway (Figure 1). Chang and
Ganem show that expression of ORF45
in LEC leads to mTORC1 activation by
way of ERK2/RSK1. It was previously
shown that KSHV ORF45 interacts with
and activates RSK1 and RSK2 and that
RSK activation by ORF45 depends on
ERK1/ERK2 but not on MEK (Kuang
et al., 2008).
These results also make an important
contribution to the debate on the origin
of KS tumor cells. Whether KS lesions
originate from infected LECs, BECs,
or endothelial precursor cells remains
contentious (Mesri et al., 2010). The
notion that LECs are the progenitor
cells for KS is supported by the observa-
tions that (1) KS spindle cells express
specific LEC markers (Weninger et al.,
1999), (2) the overall gene expression
profile of KS is closest to that of LECs
(Wang et al., 2004), (3) in vitro experi-
ments showed that LECs support KSHV
infection more efficiently than BECs
(Wang et al., 2004), and (4) KS seldom
develops in organs lacking a lymphatic
system. The fact that posttransplant KS
responds readily to mTOR inhibition and
the new observation that infected LECs,
but not BECs, are sensitive to rapamycin
argue in favor of the LEC-origin hypothe-
sis for KS.13, April 17, 2013 ª2013 Elsevier Inc. 373
Figure 1. A Unique Transcriptional Program in KSHV-Infected
Lymphatic Endothelial Cells Leads to mTOR Activation
KSHV-infected blood vessel endothelial cells (BECs) exhibit the classic latent
virus program, including the expression of LANA, vcyclin, vFLIP, and the virus-
encoded microRNAs. Persistently infected lymphatic endothelial cells (LECs)
reveal the expression of numerous virus transcripts usually associated with
lytic infection, including ORF45. Expression of ORF45 is sufficient to activate
ERK2, which in turn phosphorylates and activates RSK1. Activated RSK1
leads to TSC2 phosphorylation, impairing the ability of TSC2 to inhibit mTOR
signaling. Other virus transcripts including vGPCR may contribute to rapamy-
cin sensitivity of KSHV-infected LEC.
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PreviewsIn summary, Chang and
Ganem show that different
endothelial lineages sup-
port fundamentally different
KSHV transcriptional pro-
grams. Their data support
the existence of a herpesvi-
ral program in which wide-
spread expression of what
previously were thought to
be exclusively lytic genes
can exist in cells that do
not produce much virus and
can continue to survive and
proliferate. This is contrary
to the dogma for herpesvi-
ruses, and although such a
state has been suggested,
this is definitive experi-
mental demonstration of
such a program. Further-
more, their data suggest
that ORF45, by way of
ERK2/RSK1/TSC2, contrib-
utes to mTORC1 depen-
dence and rapamycin sensi-
tivity. An expanded viral
transcription program during
persistent infection could
make KSHV an easier tar-
get for host immune recog-
nition. The advantage to
the virus of this expanded
gene expression program
during ‘‘latency’’ remains to
be discovered. Many other
questions remain, including
whether ORF45 is actually
expressed in the majority of
KS tumor cells, rather than
in the fraction of lytic-in-fected cells observed in KS lesions.
Does this ‘‘dysregulated lytic program’’
exist in other cell types, or is this peculiar
to LECs? What are the functions of374 Cell Host & Microbe 13, April 17, 2013 ªclassic lytic genes during persistent
infection? What is the contribution of
other viral proteins known to activate
the mTOR pathway (including vGPCR2013 Elsevier Inc.[Sodhi et al., 2006]) to rapa-
mycin sensitivity in vivo?
Future research should pro-
vide answers.REFERENCES
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